function mrInclude3() { 
	document.write("<div class='StoryText'><div class='NewsIndexDate'>18-Mar-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201003/1395085_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>16-Mar-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201003/1394184_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients </a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>14-Mar-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201003/1393715_5_2.html\",680,850,\"Y\",\"Y\");return false;'>NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div>");
}

function mrInclude20() { 
	document.write("<div class='StoryText'><div class='NewsIndexDate'>18-Mar-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201003/1395085_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>16-Mar-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201003/1394184_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients </a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>14-Mar-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201003/1393715_5_2.html\",680,850,\"Y\",\"Y\");return false;'>NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>10-Mar-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201003/1392318_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis announces USD 5 billion bond issue</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>26-Feb-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201002/1389239_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Shareholders approve all proposed resolutions of Novartis Board of Directors</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>22-Feb-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201002/1386852_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis oral multiple sclerosis development compound Gilenia®* (FTY720) granted US priority review status</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>22-Feb-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201002/1386845_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>19-Feb-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201002/1386313_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis drug Tasigna® receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>09-Feb-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201002/1381968_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>26-Jan-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201001/1377026_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>20-Jan-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201001/1375459_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression as published in New England Journal of Medicine</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>20-Jan-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201001/1375090_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>18-Jan-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201001/1374141_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis providing equivalent of over USD 2.5 million in immediate emergency aid for victims of Haiti earthquake</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>11-Jan-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201001/1371914_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis launches schizophrenia treatment Fanapt in the US, offering patients an attractive alternative to existing medications</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>04-Jan-2010</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/201001/1369739_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis to acquire majority control of Alcon, a global leader in eye care, and proposes merger for full ownership</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>23-Dec-2009</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/200912/1366823_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III project relaxin for treatment of acute decompensated heart failure</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>21-Dec-2009</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/200912/1365351_5_2.html\",680,850,\"Y\",\"Y\");return false;'>All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization (WHO) for use in developing world</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>18-Dec-2009</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/200912/1365021_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis meningococcal vaccine Menveo® recommended for approval in the European Union for prevention of disease in adolescents and adults</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>09-Dec-2009</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/200912/1359994_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis set to sustain its leading global position in oncology with portfolio targeting various tumors and life-threatening diseases</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div><div class='StoryText'><div class='NewsIndexDate'>08-Dec-2009</div><div class='NewsIndexTitle'><a href='javascript:;' onClick='openwin(\"http://cws.huginonline.com/N/134323/PR/200912/1359764_5_2.html\",680,850,\"Y\",\"Y\");return false;'>Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia</a></div><div class='NewsIndexDivider'><img src='/pkg_cfg/b.gif' width='1' height='1' alt=''></div>");
}